Product Launch

New GLP-1 Analog Catalog Line — 50 Ready-to-Ship SKUs

Responding to surging demand in the metabolic disease space, we have launched 50 new GLP-1 receptor agonist analogs available for immediate dispatch in research and GMP grades. The new catalog includes Semaglutide, Tirzepatide, Liraglutide, and 47 novel analogs with purity ≥98% guaranteed by RP-HPLC.

4 min read
Read More →

Showing 12 of 12 articles

New GLP-1 Analog Catalog Line — 50 Ready-to-Ship SKUs
Product Launch

New GLP-1 Analog Catalog Line — 50 Ready-to-Ship SKUs

Responding to surging demand in the metabolic disease space, we have launched 50 new GLP-1 receptor agonist analogs available for immediate dispatch in research and GMP grades. The new catalog includes Semaglutide, Tirzepatide, Liraglutide, and 47 novel analogs with purity ≥98% guaranteed by RP-HPLC.

4 min readRead More
Multi-Year Supply Agreement Signed with Top-5 European Pharma
Partnership

Multi-Year Supply Agreement Signed with Top-5 European Pharma

keruihk has entered a multi-year exclusive supply agreement for three oncology peptide APIs with a leading European pharmaceutical company, valued at over $45M. The agreement covers GMP-grade supply of three proprietary peptide APIs for Phase III clinical trials and commercial launch.

5 min readRead More
ICH Q7 Third-Party Audit Completed — Zero Critical Findings
Regulatory

ICH Q7 Third-Party Audit Completed — Zero Critical Findings

keruihk successfully completed its annual ICH Q7 third-party compliance audit with zero critical findings and only two minor observations, both resolved within 30 days. The audit covered all 8 synthesis suites, the analytical QC laboratory, and the cold-chain logistics center.

3 min readRead More
keruihk Scientists Publish on Novel Continuous-Flow Synthesis Platform
Research

keruihk Scientists Publish on Novel Continuous-Flow Synthesis Platform

Our R&D team has published a peer-reviewed paper in the Journal of Peptide Science describing our proprietary continuous-flow synthesis platform, which reduces synthesis time by 40% and improves yield for complex long-chain peptides (>40 amino acids). The platform is now available for custom synthesis projects.

7 min readRead More
keruihk Ranked #3 in Global Peptide CRO/CMO Survey 2025
Company Update

keruihk Ranked #3 in Global Peptide CRO/CMO Survey 2025

keruihk has been ranked #3 globally in the annual Peptide Science & Technology CRO/CMO survey, up from #7 in 2024. The ranking evaluates quality systems, delivery reliability, technical capability, and customer satisfaction across 200+ respondents from pharma and biotech companies.

3 min readRead More
FDA Guidance Update on Peptide API Manufacturing — Key Takeaways
Industry News

FDA Guidance Update on Peptide API Manufacturing — Key Takeaways

The FDA has released updated guidance on peptide API manufacturing under 21 CFR Part 211, with new requirements for impurity profiling and process validation. keruihk's QA team has reviewed the guidance and confirmed full compliance. We summarize the key changes and their impact on peptide manufacturers.

8 min readRead More
Distribution Partnership Established in Japan and South Korea
Partnership

Distribution Partnership Established in Japan and South Korea

keruihk has signed distribution agreements with two leading life science distributors in Japan and South Korea, expanding our Asia-Pacific presence. The partnerships will provide local regulatory support, warehousing, and customer service for research and pharmaceutical customers in both markets.

4 min readRead More
Newsletter

Stay Ahead in
Peptide Science

Join 5,000+ pharmaceutical and biotech professionals who receive our monthly newsletter — covering product launches, regulatory updates, and industry insights.

  • New product launches & catalog updates
  • Regulatory news & compliance updates
  • Industry trends & market insights
  • Company milestones & partnerships

Subscribe to Our Newsletter

Monthly digest, no spam. Unsubscribe anytime.

By subscribing, you agree to our Privacy Policy. No spam, ever.